Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer treatment in hours, not weeks: new One-Day radiation trial shows promise

NCT ID NCT06236516

Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new way to deliver high-dose radiation to small lung tumors in just one day, instead of the usual two to three weeks. Ten patients with early-stage lung cancer or limited lung metastases received a single session of stereotactic body radiotherapy (SBRT) using advanced imaging and adaptive planning, skipping the separate simulation appointment. The goal was to see if this faster, all-in-one approach is feasible and could make treatment more accessible for patients who live far from cancer centers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
One-fraction stereotactic body radiotherapy (SBRT) using HyperSight and Ethos devices
What this could lead to
If successful, this workflow could allow patients with small lung tumors to receive curative radiation in a single day, greatly reducing travel and wait times.
What could go wrong
This is a very small feasibility study with only 10 participants. The approach may not work for all tumor types or locations, and technical issues could prevent completion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

10 people

The number who actually took part.

Started

Feb 2024

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * One of the following diagnoses: * Histologically or radiographically diagnosed stage I-IIA (AJCC, 8th ed.) non-small cell lung cancer . * Clinical AJCC stage I defined as stage 1A1 (T1a1N0M0, T1a tumor less than or equal to 1 cm), stage 1A2 (T1bN0M0, T1b tumor between 1 and 2 cm), and stage 1A3 (T1cN0M0, T1c tumor between 2 and 3 cm). * Clinical AJCC stage IB defined as T2aN0M0, T2a tumor between 3 and 4 cm. * Clinical AJCC stage IIA defined as T2bN0M0, T2b tumor between 4 and 5 cm. * Oligometastatic lung tumor secondary to a primary cancer of any type/histology. Oligometastatic patients may include patients with: * 1-5 sites of metastatic disease with at least one lung lesion intended to be treated with SBRT * More than 5 sites of metastatic disease with oligo-progressive disease in the lung intended to be treated with SBRT. * Lesions must be small and peripheral. * Small is defined as max tumor dimension of 5 cm or less. * Peripheral is defined as greater than 2 cm from the proximal bronchial tree/mediastinum. * Tumors and anatomy amenable to one-fraction lung SBRT confirmed by meeting of one-fraction lung SBRT target and constraint metrics on a diagnostic-scan based preplan. * Patients who do not meet this criterion will be screen fails and triaged to the standard lung SBRT workflow and treated off trial. * Lesions must have a maximum superior to inferior motion of 1 cm on 4D-CT imaging. * Patients who do not meet this criteria will be screen fails and triaged to the standard lung SBRT workflow and treated off trial. * At least 18 years of age. * Able to understand and willing to sign an IRB approved written informed consent. Exclusion Criteria: * Past history of radiotherapy within the projected treatment field of any of the disease sites to be treated by ONE STOP SBRT. * Pregnant and/or breastfeeding. Patient must have a negative pregnancy test within 14 days of ONE STOP SBRT.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer Oligometastatic lung tumor

Contacts and locations

Locations

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.